Jan Malcolm, a director at United Therapeutics Corp (NASDAQ:UTHR), executed a sale of 325 shares of the company's common stock on July 10, 2026. The transaction resulted in a total value of $178,941, with each share sold at a price of $550.59. This move followed a prior acquisition of 650 shares by Ms. Malcolm on July 9, 2026, which occurred due to the vesting of restricted stock units.
The sale was conducted under a pre-arranged 10b5-1 plan that Ms. Malcolm established on September 11, 2025. Following this transaction, Ms. Malcolm directly holds 450 shares of United Therapeutics common stock. The company's stock has delivered an 84% return over the past year and is currently trading at $547.06, with a market capitalization of $23.3 billion. According to InvestingPro analysis, the company maintains a "GREAT" financial health score but appears overvalued relative to its Fair Value estimate.
On July 9, 2026, Ms. Malcolm acquired 650 shares of common stock at a price of $0.00 per share. These shares were received upon the vesting of restricted stock units, which converted into common stock on a one-for-one basis. Prior to these transactions, Ms. Malcolm held 775 shares directly. After the vesting, no restricted stock units remained in her direct ownership.
In other recent developments, United Therapeutics announced the U.S. Food and Drug Administration's approval of its LungFX device for centralized ex vivo lung perfusion. This device is intended to evaluate donor lungs outside the body, potentially improving the transplantation process. Additionally, United Therapeutics reported that its phase 3 study of nebulized Tyvaso for idiopathic pulmonary fibrosis met its primary endpoint, as published in the New England Journal of Medicine. The study showed that Tyvaso preserved lung function and reduced the risk of clinical worsening events.
TD Cowen reiterated a Buy rating on United Therapeutics, maintaining a price target of $675.00. The firm hosted a key opinion leader investor lunch featuring a leading pulmonologist involved in the TETON studies. Meanwhile, BETA Technologies completed the first electric aircraft flights under the FAA's eVTOL Integration Pilot Program. These flights covered approximately 275 nautical miles across four airports in Virginia and Maryland.
United Therapeutics' stock performance and insider activity reflect ongoing scrutiny within the biotechnology sector. The company's recent regulatory approvals and clinical trial results highlight its focus on pulmonary care and transplantation technologies. However, the overvaluation noted by analysts suggests potential risks for investors. The insider sale, while pre-arranged, may signal caution among company leadership regarding current stock levels.